Sign in Subscribe
BioMed

🧬 BioMed Pulse · 2026-09-11 02:02 UTC

BIOMED PULSE

Friday, September 11, 2026 | Your daily briefing on longevity, viruses, and new cures

⚡ TL;DR

The Bundibugyo virus Ebola outbreak in the Democratic Republic of the Congo has now reached 61 health zones across six provinces, making it the largest Ebola outbreak ever recorded in DRC — and it is still accelerating. Elsewhere, a landmark cellular senescence paper reframes aging as a failure of endocrine communication, adding biological depth to the urgency of the outbreak-heavy week.

🦠 OUTBREAKS & VIRUSES

BUNDIBUGYO VIRUS DISEASE (EBOLA), DRC AND UGANDA — CRITICAL UPDATE

  • As of September 10, 2026, the DRC Bundibugyo virus disease (BVD) outbreak has expanded to 61 health zones across six provinces: Bas-Uele, Haut-Uele, Ituri, North Kivu, South Kivu, and Tshopo, with Kayna in North Kivu the newest addition. [1]
  • The WHO DON published August 28 recorded 60 affected health zones; the single new zone added since then signals ongoing, uncontrolled spread. [2] [1]
  • The August 14 WHO report called this the largest Ebola outbreak ever reported in DRC and stated it is expanding faster than any previous Ebola outbreak, driven by sustained transmission in dense population corridors. [3]
  • By July 17, cumulative confirmed cases had reached 2,124 with 828 deaths reported from DRC; figures have continued rising with each successive WHO report. [4]
  • Cross-border transmission to Uganda has been confirmed since the May 15 joint declaration by both health ministries; CDC mobilized an international response beginning May 17. [5] [6] [7]
  • CDC activated enhanced Ebola airport screening at Washington-Dulles International Airport on May 21 and expanded screening to Atlanta Hartsfield-Jackson on May 23. [8] [9]

ANDES HANTAVIRUS, M/V HONDIUS CRUISE SHIP — ONGOING

  • The fifth WHO Disease Outbreak News update (July 2, 2026) confirmed the outbreak aboard M/V Hondius remains active; the pathogen is Andes hantavirus (ANDV), a rodent-borne orthohantavirus causing severe pulmonary syndrome. [10]
  • The initial WHO notification on May 2 flagged seven cases (two laboratory-confirmed) among 147 passengers and crew; case counts rose with each successive DON through late June.
  • CDC issued multiple briefing transcripts through June 24 and is maintaining active monitoring of disembarked passengers across multiple countries.

MEASLES, BANGLADESH — ONGOING

  • WHO notified on April 23, 2026 of a nationwide measles surge in Bangladesh affecting 58 of 64 districts across all eight divisions, with 19,161 suspected cases and 2,897 laboratory-confirmed cases reported.

YELLOW FEVER — AMERICAS, 2026

  • WHO's June 24 global summary recorded 79 human infections across six countries from January 1 to May 26, 2026, representing continued spillover from elevated 2025 transmission in the Americas; spread is via Aedes and Haemagogus mosquitoes.

NIPAH VIRUS, INDIA — ISOLATED CASE UNDER WATCH

  • On June 11, 2026, Kerala State Health Department confirmed one laboratory-confirmed case of Nipah virus (NiV) in Kozhikode district; the adult male developed neurological symptoms on May 30 and was hospitalized June 10, 2026.

WEST NILE VIRUS, UNITED STATES — EARLY SEASON SURGE

  • CDC reported on July 1, 2026 that the 2026 West Nile season is running ahead of historical baselines with record early case counts; the agency issued a public advisory urging repellent use during the Independence Day holiday period.

CYCLOSPORA, UNITED STATES — TACO BELL LETTUCE OUTBREAK

  • As of July 17, 2026, 1,644 people across at least five states were confirmed ill with Cyclospora cayetanensis infections traced to shredded iceberg lettuce served at Taco Bell locations; the outbreak subsequently expanded to four additional states by July 24.

SALMONELLA — MULTIPLE ACTIVE OUTBREAKS

  • CDC posted a Salmonella alert on September 5, 2026 linking 16 illnesses in 10 states to Metabolic Meals home-delivery foods; investigation is ongoing.
  • A separate August 21 alert tied both E. coli and Salmonella illnesses to recalled alfalfa sprouts distributed multistate.
  • The Salmonella outbreak linked to jalapeños was flagged August 5, 2026.

LISTERIA — PREPARED MEALS OUTBREAK EXPANDING

  • CDC confirmed on September 26, 2025 that the ongoing Listeria monocytogenes prepared-meals outbreak expanded to include additional products, with three more illnesses and one additional death added to the case count.

DRUG-RESISTANT BACTERIA — SHARP NATIONAL RISE

  • A September 23, 2025 CDC report documented a dramatic increase in dangerous drug-resistant bacteria across U.S. healthcare settings, compounding existing concerns about carbapenem-resistant organisms.

🧬 LONGEVITY & AGING

CELLULAR SENESCENCE AS ENDOCRINE SIGNALING FAILURE

  • A new paper in Ageing Research Reviews (Bi Z, Lin Y) proposes that cellular senescence is fundamentally a breakdown in endocrine information transfer: senescent cells emit a senescence-associated secretory phenotype (SASP) that disrupts hormone-like signaling networks governing tissue maintenance, repositioning senescence as a systemic communication failure rather than merely a local cell-fate event.

SENESCENCE-TARGETING VESICLES AGAINST DISC DEGENERATION

  • Researchers published in Biomaterials (Shi P et al.) an injectable hydrogel microsphere system loaded with senescence-targeting apoptotic extracellular vesicles that mitigated ferroptosis — an iron-dependent form of cell death — in nucleus pulposus cells of degenerating intervertebral discs in preclinical models, suggesting a dual senolytic-ferroptosis axis for disc aging.

YOUNG PLASMA EXOSOMES FOR ALZHEIMER'S DISEASE

  • A Bioactive Materials study (Chen H et al., August 15, 2026) characterized engineered exosomes derived from young plasma and demonstrated therapeutic activity in Alzheimer's disease models, including reduced amyloid burden and improved synaptic markers, advancing the concept that age-related extracellular vesicle composition changes drive neurodegeneration.

EGFR LOSS IN AGED BONE STEM CELLS IMPAIRS FRACTURE HEALING

  • Work in Bioactive Materials (Hu Y et al., August 4, 2026) showed that loss of epidermal growth factor receptor (EGFR) activity specifically in skeletal stem and progenitor cells is mechanistically associated with the well-known decline in fracture healing seen in aged mice, identifying EGFR restoration as a potential bone-regeneration target in older adults.

MRNA LIPID NANOPARTICLE RESTORES ABCA1 CHOLESTEROL BALANCE IN AGED BONE

  • A dual-targeting mRNA lipid nanoparticle (Bioactive Materials, Cheng M et al., August 20, 2026) restored ABCA1-dependent cholesterol homeostasis in aged bone tissue and promoted repair of age-related bone defects in vivo, extending mRNA nanomedicine concepts beyond the cardiovascular field into geroscience.

ANTIOXIDANT AND EPIGENETIC DUAL THERAPY BREAKS THE SENESCENCE CYCLE IN OSTEOARTHRITIS

  • Published in Bioactive Materials (An X et al., July 31, 2026), a dual-modal approach combining antioxidant treatment with epigenetic reprogramming interrupted the self-reinforcing SASP-senescence cycle in osteoarthritic cartilage, with the authors framing the paracrine spread of senescence as a central disease mechanism.

SPINAL VERSUS GENERAL ANAESTHESIA IN OLDER HIP FRACTURE PATIENTS

  • A multicenter randomized clinical trial from Germany (Kowark A et al., Lancet Healthy Longevity) compared spinal and general anaesthesia in older patients undergoing hip fracture surgery; a linked editorial by Moppett and Shelton questioned whether the long-running debate should now be considered resolved, implying the trial provides sufficiently definitive evidence.

DEPRESCRIBING TRIALS NEED RATIONALE-FIRST DESIGN FRAMEWORKS

  • Two linked commentaries in Lancet Healthy Longevity (Hwang CS et al.; Van der Linden LR) argued that deprescribing trials in older adults must define the mechanistic and clinical rationale before selecting trial design, warning that method-first approaches have produced inconclusive results across polypharmacy studies.

DEMENTIA AND CANCER INCIDENCE: SEX-SPECIFIC ECOLOGICAL ANALYSIS

  • A sex-stratified ecological study across countries (You W et al., Future Science OA, September 4, 2026) examined the inverse relationship between cancer incidence and dementia incidence, adding epidemiological weight to theories involving shared cellular-aging mechanisms — notably p53 and senescent cell clearance pathways — that may differentially protect against one condition while increasing risk of the other.

💊 NEW CURES & APPROVALS

ZANVASTRO (ZILGANERSEN) — IONIS PHARMACEUTICALS, ORIGINAL APPROVAL

  • Ionis Pharmaceuticals received an original FDA approval (NDA220210) for Zanvastro, with the active ingredient zilganersen; zilganersen is an antisense oligonucleotide designed to reduce glial fibrillary acidic protein (GFAP) expression, targeting Alexander disease, a rare and fatal leukodystrophy caused by GFAP mutations.

AVTOZMA (TOCILIZUMAB-ANOH) — CELLTRION, SUPPLEMENTAL APPROVALS

  • Celltrion received supplemental approvals (BLA761498 and BLA761420) for Avtozma, a biosimilar of tocilizumab (IL-6 receptor antagonist); tocilizumab biosimilars are used in rheumatoid arthritis, giant cell arteritis, cytokine release syndrome, and other inflammatory indications.

SACUBITRIL AND VALSARTAN — AUROBINDO PHARMA, ORIGINAL GENERIC APPROVAL

  • Aurobindo Pharma received an original ANDA approval (ANDA213631) for the sacubitril/valsartan combination, the neprilysin inhibitor/ARB heart failure tablet class pioneered by Entresto; this generic entry broadens access for patients with reduced-ejection-fraction heart failure.

ALENDRONATE SODIUM — PRECISION DOSE, ORIGINAL APPROVAL

  • Precision Dose received an original ANDA approval (ANDA214523) for an alendronate sodium oral solution formulation, expanding dosing options for bisphosphonate therapy in osteoporosis patients who cannot swallow tablets.

FYARRO (SIROLIMUS ALBUMIN-BOUND) — AADI, SUPPLEMENTAL APPROVAL

  • AADI received a supplemental approval (NDA213312) for Fyarro, an albumin-bound form of sirolimus (an mTOR inhibitor); it is indicated for perivascular epithelioid cell tumors (PEComas) and its mTOR-pathway mechanism has independent interest in geroscience given mTOR's central role in aging biology.

CIBINQO (ABROCITINIB) — PFIZER, SUPPLEMENTAL APPROVAL

  • Pfizer received a supplemental approval (NDA213871) for Cibinqo (abrocitinib), a JAK1-selective inhibitor used in moderate-to-severe atopic dermatitis; JAK inhibitors are also under active investigation in senescence and inflammaging research contexts.

DAPAGLIFLOZIN — AJANTA PHARMA, SUPPLEMENTAL APPROVAL

  • Ajanta Pharma received a supplemental ANDA approval (ANDA211482) for dapagliflozin, an SGLT2 inhibitor with indications spanning type 2 diabetes, heart failure, and chronic kidney disease; SGLT2 inhibitors have attracted longevity-research attention for their effects on mitochondrial function and cellular stress pathways.

🧪 CLINICAL TRIALS

ALZHEIMER'S BLOOD BIOMARKER DECISION-SUPPORT TOOL IN PRIMARY CARE

  • A new ClinicalTrials.gov registration (NCT07812337, registered September 10, 2026) will evaluate a decision-support tool designed to help primary care providers communicate with patients about blood biomarker testing for Alzheimer's disease, targeting improvements in shared decision-making before testing is ordered.

LACTOBACILLUS ACIDOPHILUS AND INULIN FOR COGNITIVE IMPAIRMENT IN OBESITY

  • A randomized crossover trial (NCT07810517, registered September 10, 2026) will test a synbiotic combining Lactobacillus acidophilus and inulin on cognitive function in 40 adults aged 30-40 with obesity and mild cognitive impairment, probing the gut-brain axis as a longevity-relevant target.

SARCOPENIA AND FUNCTIONAL RECOVERY AFTER HIP ARTHROPLASTY IN ADULTS OVER 75

  • A single-center exploratory study at Montpellier University Hospital (NCT07429955) will enroll approximately 20 volunteers aged 75 or older undergoing hip replacement to assess whether pre-operative sarcopenia — low muscle mass and strength — predicts failure to regain everyday independence, with implications for prehabilitation protocols.

SACROPLASTY FOR SACRAL INSUFFICIENCY FRACTURES IN ADULTS OVER 50

  • Trial NCT07493564 will determine whether sacroplasty, a minimally invasive cement-injection procedure, improves quality of life and functional recovery in adults aged 50 or older with sacral fragility fractures, common and debilitating injuries in the osteoporotic older population.

EXTRACELLULAR VESICLE STRATEGY TO ASSESS ISLET FITNESS BEFORE TRANSPLANTATION

  • Trial NCT07812974 (registered September 10, 2026) will use extracellular vesicle profiling to stratify and improve pancreatic islet fitness before transplantation in people with high-glycemic-variability diabetes; baseline data show 90% of prior recipients were free from severe hypoglycaemia at five years post-transplant.

MIRABEGRON PLUS ALPHA-LIPOIC ACID FOR OBESITY

  • Trial NCT05713799 is evaluating the beta-3 adrenergic agonist mirabegron combined with the antioxidant supplement alpha-lipoic acid for obesity treatment, targeting brown adipose tissue activation and oxidative stress reduction; obesity is a primary accelerant of biological aging.

📢 PUBLIC HEALTH

CONGENITAL SYPHILIS RISES FOR 12TH CONSECUTIVE YEAR IN U.S.

  • CDC data released September 24, 2025 showed U.S. cases of syphilis in newborns increased for the 12th consecutive year in 2024, underscoring a persistent failure in prenatal screening and treatment systems.

TIMOR-LESTE CERTIFIED MALARIA-FREE BY WHO

  • On July 23-24, 2025, WHO certified Timor-Leste as malaria-free, recognizing a nationwide elimination effort begun shortly after the country's independence in 2002 — a public health milestone for Southeast Asia.

U.S. COMPLETED WHO WITHDRAWAL JANUARY 22, 2026

  • The United States formally completed its withdrawal from the World Health Organization on January 22, 2026, citing COVID-19 response failures and alleged politicization; WHO expressed in a January 24 statement that the withdrawal "makes both the United States and the world less safe."

CDC CHILDHOOD IMMUNIZATION SCHEDULE UPDATED PER PRESIDENTIAL MEMO

  • Acting CDC Director Jim O'Neill signed a decision memorandum on January 4, 2026, updating the childhood immunization schedule in response to a Presidential Memorandum; a subsequent October 2025 update had already shifted COVID-19 vaccination to individual-based decision-making and separated chickenpox vaccination for toddlers.

DRUG OVERDOSE DEATHS DOWN 27% IN 2024

  • CDC's National Vital Statistics System data released May 14, 2025 recorded a 27% decrease in drug overdose deaths in 2024, building on a 24% decline reported in February 2025 and representing the sharpest back-to-back improvement in decades.

This briefing is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare provider for clinical decisions.

📎 Sources

  1. Ebola disease caused by Bundibugyo virus - Democratic Republic… — WHO Disease Outbreak News
  2. Ebola disease caused by Bundibugyo virus - Democratic Republic… — WHO Disease Outbreak News
  3. Ebola disease caused by Bundibugyo virus - Democratic Republic… — WHO Disease Outbreak News
  4. Ebola disease caused by Bundibugyo virus, Democratic Republic … — WHO Disease Outbreak News
  5. Ebola disease caused by Bundibugyo virus, Democratic Republic … — WHO Disease Outbreak News
  6. Ebola disease caused by Bundibugyo virus – Democratic Republic… — WHO Disease Outbreak News
  7. CDC Mobilizes International Response Following Ebola Disease O… — CDC Newsroom
  8. Enhanced Ebola Airport Screening Begins at Washington-Dulles I… — CDC Newsroom
  9. Enhanced Ebola Airport Screening Expands to Atlanta — CDC Newsroom
  10. Hantavirus outbreak linked to cruise ship travel, Multi-locations — WHO Disease Outbreak News

Curated from official sources — WHO/CDC/ECDC/openFDA/ClinicalTrials.gov/Europe PMC. Informational only — not medical advice.
Serial 20260911-02-v72 · 2026-09-11 02:02 UTC · pulse.uzylab.com

Read next